Contribute Try STAT+ Today

Amid intense debate over equitable access to Covid-19 vaccines, the European Union is offering a rival plan to a controversial proposal that would temporarily waive intellectual property protections in a World Trade Organization Agreement. But critics say the alternative is inadequate.

The proposed plan is designed to safeguard patent rights, a hot-button issue for the pharmaceutical industry and some EU countries where drug makers are based. Instead, the EU suggested several ideas to increase equitable vaccine distribution, such as limiting export restrictions, voluntary licensing, sharing expertise, tiered pricing, making it easier for countries to use existing rules to override patents in some cases, and new investments in manufacturing plants in developing countries (part one and part two).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.